Recruiting

Phase 2

Dasatinib, Quercetin, CAR-TDasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Sponsor:

Mayo Clinic

Code:

NCT06940297

Conditions

Recurrent Multiple Myeloma

Refractory Multiple Myeloma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biopsy Procedure

Biospecimen Collection

Bone Marrow Aspiration

Bone Marrow Biopsy

Ciltacabtagene Autoleucel

Study Details

Brief summary:

This phase II trial tests how well giving dasatinib and quercetin with cyclophosphamide, fludarabine and chimeric antigen receptor (CAR)-T cell therapy works in treating patients with multiple myeloma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Dasatinib is in a class of medications called tyrosine kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply, which may help keep cancer cells from growing. Quercetin is a compound found in plants that may prevent multiple myeloma from forming. Chemotherapy such as cyclophosphamide and fludarabine are given to help kill any remaining cancer cells in the body and to prepare the bone marrow for CAR-T therapy. Chimeric antigen receptor T-cell Therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. Giving dasatinib and quercetin with cyclophosphamide, fludarabine and CAR-T cell therapy may kill more cancer cells in patients with relapsed or refractory multiple myeloma.

Conditions

Recurrent Multiple Myeloma

Refractory Multiple Myeloma

Study ID

NCT06940297

Start date

Sep 18, 2025

Status verified date

Aug, 2026

Completion date

Aug 15, 2031

Anticipated

Primary completion date

Aug 15, 2031

Anticipated

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

Age ≥ 18 years
Relapsed or refractory multiple myeloma who has had at least 3 prior lines of therapies including a proteasome inhibitor, immunomodulatory drug (IMiD) and anti-CD38 monoclonal antibody (mAb)
Ciltacabtagene autoleucel (Carvykti) available for patient
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2
Life expectancy ≥ 12 weeks
Hemoglobin ≥ 8.0 g/dL (obtained ≤ 14 days prior to registration)
Absolute neutrophil count (ANC) ≥ 1,000/mm\^3 (obtained ≤ 14 days prior to registration)
Platelet count ≥ 50,000/mm\^3 (obtained ≤ 14 days prior to registration)
Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (obtained ≤ 14 days prior to registration)

Note: Patients with Gilbert's syndrome must have a total bilirubin of ≤ 3 x ULN (obtained ≤ 14 days prior to registration)
Alanine aminotransferase (ALT) and aspartate transaminase (AST) ≤ 2 x ULN (obtained ≤ 14 days prior to registration)
Alkaline phosphatase ≤ 1.5 x ULN (obtained ≤ 14 days prior to registration)
Calculated creatinine clearance ≥ 30 ml/min using the Cockcroft-Gault formula (obtained ≤ 14 days prior to registration)
Negative pregnancy test done ≤ 7 days prior to registration, for persons of childbearing potential only

Note: If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Sexually active patients and their partners must use an effective method of contraception associated with a low failure rate prior to study entry and for the duration of study participation and for at least 30 days after the last dose of study drug
Provide written informed consent
Willingness to provide mandatory blood and bone marrow specimens for correlative research
Willingness to provide mandatory bone marrow cores and/or tissue specimens for correlative research
Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)

Exclusion Criteria:

Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or AL amyloidosis
Failure to recover from acute, reversible effects of prior therapy regardless of interval since last treatment.

EXCEPTION: Grade 1 peripheral (sensory) neuropathy that has been stable for at least 1 month since completion of prior treatment
Any of the following because this study involves an agent that has known genotoxic, mutagenic, and teratogenic effects:

Pregnant persons
Nursing persons
Persons of childbearing potential (and persons able to father a child) who are unwilling to employ adequate contraception
Major surgery ≤ 28 days prior to registration
Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
Immunocompromised patients and patients known to be HIV positive.

NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, or those currently receiving antiretroviral therapy with good control of HIV, are eligible for this trial
Evidence of cardiovascular disease risk, as defined by any of the following:

Evidence of current clinically significant uncontrolled arrhythmias, including clinically significant ECG abnormalities such as 2nd degree (Mobitz Type II) or 3rd degree atrioventricular (AV) block
History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting within three (3) months of screening.
Class III or IV heart failure as defined by the New York Heart Association functional classification system
Uncontrolled hypertension
History of life-threatening ventricular arrhythmias
Uncontrolled intercurrent illness including, but not limited to:

Ongoing or active infection
Any medical condition that would make participation unduly hazardous
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Live vaccine ≤ 6 weeks prior to registration
Has taken a strong inhibitor or inducer of CYP3A4/5, including grapefruit, St. John's Wort or related products ≤ 14 days prior to registration.

Note: If required, patients may receive a short course of strong inhibitors or inducers for treatment of symptoms, but dasatinib dose must be adjusted as indicated
Known hypersensitivity or allergy to dasatinib or quercetin
Patients on therapeutic doses of anticoagulants (e.g. warfarin, heparin, low molecular weight heparin, factor Xa inhibitors, etc).
On antiplatelet agents (e.g. full dose aspirin, clopidogrel etc.)

NOTE: Baby aspirin, if necessary for cardioprotection, will be allowed
On quinolone antibiotic therapy for treatment or for prevention of infections products ≤10 days prior to registration

Study Design

Enrollment

44 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Treatment (Dasatinib, quercetin, chemotherapy, CAR-T)

Patients receive dasatinib by mouth (PO) once a day (QD) and quercetin PO twice a day (BID) on days -7 and -6 and cyclophosphamide IV over 60 minutes and fludarabine IV over 30 minutes on days -5 to -3 in the absence of disease progression or unacceptable toxicity. Patients then receive CAR-T IV on day 0. Patients receive dasatinib PO QD and quercetin PO BID on days 28, 29, 58, 59, 88 and 89 in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan and/or PET, tumor biopsy, bone marrow aspirate and biopsy and blood sample collection throughout the study.

Interventions

Biopsy Procedure

Undergo tumor biopsy

Biospecimen Collection

Undergo blood sample collection

Bone Marrow Aspiration

Undergo bone marrow aspiration

Bone Marrow Biopsy

Undergo bone marrow biopsy

Ciltacabtagene Autoleucel

Given IV

Computed Tomography

Undergo CT scan

Cyclophosphamide

Given IV

Dasatinib

Given PO

Fludarabine

Given IV

Positron Emission Tomography

Undergo PET scan

Quercetin

Given PO

Primary outcome measure

Minimal residual disease (MRD) negativity rate [ Time Frame: At 3 months ]

Central Contacts and Locations

Central contacts

Clinical Trials Referral Office

855-776-0015 mayocliniccancerstudies@mayo.edu

Locations

Mayo Clinic in Rochester

Recruiting

Rochester, Minnesota, United States, 55905

Contacts

Clinical Trials Referral Office

855-776-0015 mayocliniccancerstudies@mayo.edu

Principal Investigator:

Yi Lin, MD, PhD

More Information

Sponsor

Mayo Clinic

Last update posted

Aug 26, 2026

Last verified

Aug, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Mayo Clinic on 2026-08-26.